Cardiogenic Shock - Pipeline Insight, 2024

Cardiogenic Shock - Pipeline Insight, 2024

DelveInsight’s, “Cardiogenic Shock – Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cardiogenic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cardiogenic Shock Understanding

Cardiogenic Shock: Overview

Cardiogenic shock is defined as systemic tissue hypoperfusion due to inadequate cardiac output (CO) despite adequate circulatory volume. Cardiogenic shock is a serious condition that occurs when your heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Cardiogenic shock is considered a medical emergency and should be treated immediately. The most common cause of cardiogenic shock is a heart attack. Other health problems that may lead to cardiogenic shock include heart conditions such as heart failure, chest injuries, medicine side effects, and conditions that prevent blood from flowing freely through your heart, such as a blood clot in the lungs.

Symptoms

The symptoms of Cardiogenic Shock include:

• Low blood pressure, dizziness
• Confused and nauseous
• Breathing problems
• Bulging of large veins in the neck
• Cold hands and feet
• Loss of consciousness
• Swelling of feet

Diagnosis

• Cardiogenic shock is usually diagnosed in an emergency setting. Electrocardiogram is used to record the electrical activity of heart via electrodes attached to skin. Echocardiogram records sound waves which produces an image of the heart that can help identify damage from a heart attack. Invasive haemodynamic assessment using pulmonary artery catheterization is not recommended for routine use, but is useful to confirm and characterize suspected shock, and is often used to manage refractory cardiogenic shock.

Treatment

Inotropes and vasopressors are the initial therapies for supporting patients with Cardiogenic Shock. All the inotropic agents, except for, levosimendan, work by increasing cyclic adenosine monophosphate (cAMP) levels which in-turn activates protein kinase A with resultant increased intracellular calcium. Temporal Mechanical Circulatory System is an integral part of management of Cardiogenic Shock and is commonly utilized as a bridge-to-decision, whether it is recovery, palliation, heart transplant or a durable MCS device. Emergent revascularization is the only therapy that has been shown to reduce mortality in patients with cardiogenic shock complicating acute myocardial Infarction.

Cardiogenic Shock Emerging Drugs Chapters

This segment of the Cardiogenic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cardiogenic Shock Emerging Drugs

• Istaroxime: Windtree Therapeutics

Istaroxime is a first-in-class, dual action, luso-inotropic agent in Phase 2 of clinical development. It is a potent positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+-ATPase. In addition, it facilitates myocardial relaxation through activation of the SERCA2a calcium pump.

Further product details are provided in the report……..

Cardiogenic Shock: Therapeutic Assessment

This segment of the report provides insights about the different Cardiogenic Shock drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cardiogenic Shock

There are approx. 3+ key companies which are developing the therapies for Cardiogenic Shock. The companies which have their Cardiogenic Shock drug candidates in the most advanced stage, i.e. phase III include, Windtree Therapeutics.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cardiogenic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cardiogenic Shock: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cardiogenic Shock therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cardiogenic Shock drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cardiogenic Shock R&D. The therapies under development are focused on novel approaches to treat/improve Cardiogenic Shock.

Cardiogenic Shock Report Insights

• Cardiogenic Shock Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cardiogenic Shock Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cardiogenic Shock drugs?
• How many Cardiogenic Shock drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cardiogenic Shock?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cardiogenic Shock therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cardiogenic Shock and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Windtree Therapeutics
• Leading BioSciences

Key Products

• Istaroxime
• Tranexamic acid